Pyxis Oncology IncNASDAQ:PYXS
- LAST PRICE3.7400
- TODAY'S CHANGE (%)0.0200 (0.5376%)
- Bid / Lots3.8000/ 1
- Ask / Lots3.8900/ 42
- Open / Previous Close3.7500 / 3.7200
- Day Range
- 52 Week Range
- Volume246,197
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PYXS |
|---|---|---|
| 09:32 ET | 1456 | 3.7767 |
| 09:36 ET | 1932 | 3.75 |
| 09:39 ET | 407 | 3.75 |
| 09:41 ET | 1801 | 3.79 |
| 09:43 ET | 6805 | 3.8 |
| 09:45 ET | 420 | 3.79 |
| 09:50 ET | 2737 | 3.775 |
| 09:52 ET | 513 | 3.775 |
| 09:56 ET | 288 | 3.8 |
| 09:59 ET | 937 | 3.8 |
| 10:01 ET | 11564 | 3.825 |
| 10:03 ET | 300 | 3.8213 |
| 10:06 ET | 4746 | 3.825 |
| 10:08 ET | 3100 | 3.7901 |
| 10:10 ET | 500 | 3.805 |
| 10:12 ET | 100 | 3.805 |
| 10:15 ET | 300 | 3.8 |
| 10:17 ET | 12777 | 3.8 |
| 10:21 ET | 1835 | 3.86 |
| 10:26 ET | 1009 | 3.8357 |
| 10:28 ET | 700 | 3.85 |
| 10:30 ET | 300 | 3.85 |
| 10:32 ET | 1097 | 3.83 |
| 10:33 ET | 2710 | 3.825 |
| 10:35 ET | 300 | 3.82 |
| 10:37 ET | 100 | 3.81 |
| 10:44 ET | 241 | 3.815 |
| 10:46 ET | 100 | 3.815 |
| 10:48 ET | 430 | 3.78 |
| 10:50 ET | 100 | 3.79 |
| 10:55 ET | 100 | 3.78 |
| 10:57 ET | 608 | 3.78 |
| 11:00 ET | 200 | 3.79 |
| 11:04 ET | 100 | 3.79 |
| 11:06 ET | 100 | 3.79 |
| 11:08 ET | 163 | 3.79 |
| 11:09 ET | 100 | 3.79 |
| 11:13 ET | 191 | 3.8 |
| 11:15 ET | 2161 | 3.795 |
| 11:24 ET | 103 | 3.79 |
| 11:27 ET | 257 | 3.79 |
| 11:29 ET | 100 | 3.78 |
| 11:31 ET | 313 | 3.79 |
| 11:33 ET | 866 | 3.7815 |
| 11:38 ET | 100 | 3.79 |
| 11:44 ET | 300 | 3.79 |
| 11:47 ET | 300 | 3.78 |
| 11:49 ET | 450 | 3.7963 |
| 11:51 ET | 508 | 3.785 |
| 11:54 ET | 100 | 3.77 |
| 11:56 ET | 200 | 3.79 |
| 12:00 ET | 200 | 3.78 |
| 12:03 ET | 100 | 3.78 |
| 12:05 ET | 100 | 3.79 |
| 12:14 ET | 1501 | 3.76 |
| 12:16 ET | 1411 | 3.785 |
| 12:18 ET | 542 | 3.775 |
| 12:21 ET | 900 | 3.78 |
| 12:23 ET | 700 | 3.79 |
| 12:25 ET | 2200 | 3.79 |
| 12:32 ET | 500 | 3.785 |
| 12:34 ET | 300 | 3.785 |
| 12:36 ET | 310 | 3.785 |
| 12:38 ET | 500 | 3.79 |
| 12:41 ET | 1245 | 3.78 |
| 12:48 ET | 600 | 3.77 |
| 12:50 ET | 500 | 3.7666 |
| 12:57 ET | 100 | 3.75 |
| 12:59 ET | 200 | 3.74 |
| 01:01 ET | 300 | 3.74 |
| 01:06 ET | 100 | 3.735 |
| 01:08 ET | 5086 | 3.7389 |
| 01:10 ET | 4140 | 3.71 |
| 01:12 ET | 921 | 3.73 |
| 01:14 ET | 200 | 3.72 |
| 01:15 ET | 200 | 3.72 |
| 01:17 ET | 2130 | 3.74 |
| 01:19 ET | 500 | 3.77 |
| 01:21 ET | 100 | 3.77 |
| 01:24 ET | 600 | 3.79 |
| 01:26 ET | 400 | 3.8 |
| 01:28 ET | 1100 | 3.8 |
| 01:30 ET | 717 | 3.8 |
| 01:32 ET | 3612 | 3.8 |
| 01:35 ET | 1687 | 3.82 |
| 01:37 ET | 1400 | 3.82 |
| 01:39 ET | 200 | 3.83 |
| 01:42 ET | 1491 | 3.84 |
| 01:44 ET | 1061 | 3.85 |
| 01:46 ET | 930 | 3.85 |
| 01:48 ET | 700 | 3.85 |
| 01:50 ET | 4222 | 3.87 |
| 01:51 ET | 4517 | 3.86 |
| 01:53 ET | 400 | 3.85 |
| 01:55 ET | 100 | 3.8513 |
| 01:57 ET | 3450 | 3.855 |
| 02:02 ET | 100 | 3.845 |
| 02:04 ET | 385 | 3.84 |
| 02:06 ET | 1217 | 3.85 |
| 02:08 ET | 5582 | 3.85 |
| 02:11 ET | 2062 | 3.84 |
| 02:13 ET | 697 | 3.84 |
| 02:18 ET | 100 | 3.84 |
| 02:20 ET | 307 | 3.84 |
| 02:22 ET | 319 | 3.85 |
| 02:24 ET | 404 | 3.84 |
| 02:26 ET | 2307 | 3.83 |
| 02:31 ET | 1300 | 3.81 |
| 02:36 ET | 301 | 3.8099 |
| 02:38 ET | 614 | 3.8 |
| 02:40 ET | 3245 | 3.79 |
| 02:42 ET | 100 | 3.785 |
| 02:44 ET | 803 | 3.7808 |
| 02:45 ET | 412 | 3.785 |
| 02:49 ET | 300 | 3.78 |
| 02:51 ET | 100 | 3.77 |
| 02:54 ET | 100 | 3.775 |
| 02:56 ET | 100 | 3.775 |
| 02:58 ET | 100 | 3.78 |
| 03:02 ET | 700 | 3.77 |
| 03:03 ET | 300 | 3.765 |
| 03:07 ET | 1349 | 3.755 |
| 03:09 ET | 100 | 3.74 |
| 03:12 ET | 200 | 3.75 |
| 03:14 ET | 100 | 3.76 |
| 03:16 ET | 100 | 3.75 |
| 03:18 ET | 509 | 3.7429 |
| 03:23 ET | 100 | 3.75 |
| 03:25 ET | 100 | 3.74 |
| 03:27 ET | 3520 | 3.73 |
| 03:32 ET | 300 | 3.72 |
| 03:36 ET | 733 | 3.725 |
| 03:38 ET | 100 | 3.725 |
| 03:39 ET | 6142 | 3.725 |
| 03:41 ET | 3704 | 3.755 |
| 03:43 ET | 1183 | 3.745 |
| 03:45 ET | 100 | 3.74 |
| 03:48 ET | 509 | 3.75 |
| 03:50 ET | 2993 | 3.75 |
| 03:52 ET | 1047 | 3.76 |
| 03:54 ET | 500 | 3.755 |
| 03:56 ET | 1546 | 3.755 |
| 03:57 ET | 5991 | 3.74 |
| 03:59 ET | 3193 | 3.74 |
May 30, 2024
Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference, from 7:30AM ET on Thursday May 30, 2024 by Dow Jones
7:30AM ET on Thursday May 30, 2024 by Dow Jones
May 16, 2024
DJ Pyxis Oncology Price Target Maintained With a $7.00/Share by HC Wainwright & Co., from 8:06AM ET on Thursday May 16, 2024 by Dow Jones
8:06AM ET on Thursday May 16, 2024 by Dow Jones
May 14, 2024
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024, from 7:30AM ET on Tuesday May 14, 2024 by Dow Jones
7:30AM ET on Tuesday May 14, 2024 by Dow JonesPress Release: Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024, from 7:30AM ET on Tuesday May 14, 2024 by Dow Jones
7:30AM ET on Tuesday May 14, 2024 by Dow Jones
May 9, 2024
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference, from 7:30AM ET on Thursday May 09, 2024 by Dow Jones
7:30AM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Pyxis Oncology Inc | 220.2M | -2.7x | --- |
Renovaro Inc | 219.8M | -1.9x | --- |
XBiotech Inc | 220.8M | -7.2x | --- |
Elevation Oncology Inc | 219.6M | -3.9x | --- |
Invivyd Inc | 219.5M | -1.0x | --- |
Eliem Therapeutics Inc | 224.3M | -14.4x | --- |
Company Information
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes PYX-201, PYX-106 and PYX-107. PYX-201, an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-107 is a CD40 agonist antibody designed to maximize its agonistic properties. Its therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its ADC and immuno-oncology (IO) programs target a range of solid tumors resistant to current standards of care.
Contact Information
- Headquarters
- 321 Harrison Avenue, 11th Floor, Suite 1BOSTON, MA, United States 02118
- Phone
- 617-453-3596
- Fax
- 302-655-5049
Executives
- Independent Chairman Of The Board
- John Flavin
- Chief Executive Officer, Director
- Lara Sullivan
- Chief Financial Officer, Chief Operating Officer
- Pamela Connealy
- Senior Vice President, Chief Business Officer
- Stephen Worsley
- Chief Medical Officer
- Ken Kobayashi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $220.2M |
|---|---|
Revenue (TTM) | $16.1M |
Shares Outstanding | 58.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.39 |
Book Value | $2.81 |
P/E Ratio | -2.7x |
Price/Sales (TTM) | 13.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -414.02% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
